Optimistic Outlook for Tectonic Therapeutic’s TX45: A Promising Candidate for Unmet Medical Needs
Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...
Tectonic shares tumble after rival drug trial termination
Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE: LLY) for chronic ...
Too Old to Operate16h
HDL Antioxidant Role in Heart Failure with Preserved Ejection Fraction
The following is a summary of “Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection ...
Eli Lilly trial update on kidney drug hurts Tectonic
Shares of Tectonic Therapeutic (NASDAQ:TECX) plunged on Tuesday after a federal website on clinical trials indicated that Eli Lilly (NYSE:LLY) has terminated a mid-stage trial for its experimental ...